Oligometastatic prostate cancer treatment

Area of Science:

• Oncology
• Urology
• Medical Imaging

Background:

• Oligometastatic prostate cancer is an intermediate stage with unique biological and clinical characteristics yet to be fully understood.
• Accurate detection of this condition is crucial for appropriate patient management.
• The transition between localized and widespread metastatic disease requires distinct therapeutic considerations.

Purpose of the Study:

• To review current evidence on treatment strategies for oligometastatic prostate cancer.
• To highlight the role of advanced imaging in identifying patients for specific therapies.
• To discuss the implications for androgen deprivation therapy in this patient group.

Main Methods:

• Review of clinical studies and available evidence on oligometastatic prostate cancer.
• Focus on the application of prostate-specific membrane antigen (PSMA) PET/CT scanning.
• Analysis of treatment outcomes, including metastasis-directed therapy and androgen deprivation therapy.

Main Results:

• Prostate-specific membrane antigen (PSMA) PET/CT improves the selection of patients with true early, low-volume oligometastatic disease.
• Metastasis-directed therapy is a viable option for selected candidates.
• Androgen deprivation therapy can potentially be delayed in oligometastatic patients with low tumor burden, though survival benefits are not yet established.

Conclusions:

• Oligometastatic prostate cancer requires tailored treatment approaches.
• Advanced imaging techniques like PSMA PET/CT are pivotal in patient selection for metastasis-directed therapy.
• Further research is needed to establish survival benefits for delayed androgen deprivation therapy in this setting.